Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer
About this episode
Eline Verreck BSc discusses the findings of a study suggesting that radiation boosts may no longer be justified after standard therapy for early breast cancer.
Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer An interview with: Eline Verreck BSc, Erasmus University Medical Centre, Surgical Oncology Department, Rotterdam, The Netherlands BARCELONA, Spain—Any benefit from an additional tumor-bed radiotherapy “boost” after completing standard therapy for early breast cancer seems no longer to be justified in this age of increasingly effective systemic treatments now being incorporated into standard breast-conserving therapy. A new study conducted in the Netherlands, with 34,504 patients followed up for a median of 8.3 years, has found that the possible small reductions of long-term local recurrence rates from using a boost no longer justify the toxicities such a boost can bring. Findings were reported at the 2026 meeting of the European Breast Cancer Conference by Eline Verreck BSc, who is a PhD candidate at Erasmus University Medical Centre’s Department of Surgical Oncology in Rotterdam. She talked about her results with the Audio Journal of Oncology’s correspondent, Peter Goodwin: AUDIO J0URNAL OF ONCOLOGY: Eline Verreck BSc IN: [GOODWIN]” Welcome to more news here from the ….. OUT: …….I’m Peter…
More episodes of Audio Journal of Oncology Podcast
- Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer
- Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity
- Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life
- Byoung Chul Cho MD PhD; AACR 2026: New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy
- Elena Garralda MD PhD, AACR 2026: Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors
- Icro Meattini MD; 2026 EBCC: Safe to Avoid Endocrine Therapy in Older Women with Low Risk Breast Cancers: EUROPA Study Interim Findings
Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.